Establishment of a system to evaluate the therapeutic effect and the dynamics of an investigational drug on ulcerative colitis using human colonic organoids

Journal of Gastroenterology

Volumn 54, Issue 7, 2019, Pages 608-620

  Nishimura, Ryu ^a   Shirasaki, Tomoaki ^a   Tsuchiya, Kiichiro ^a   Miyake, Yoshihide ^b   Watanabe, Yusuke ^b   Hibiya, Shuji ^a   Watanabe, Sho ^a   Nakamura, Tetsuya ^a   Watanabe, Mamoru ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b KAKEN PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Evaluation system; In vitro human model; Inflammatory bowel disease; Investigational drug

Indexed keywords

ANTIINFLAMMATORY AGENT; KAG 308; MUCIN 2; PROSTAGLANDIN RECEPTOR STIMULATING AGENT; REACTIVE OXYGEN METABOLITE; TREFOIL FACTOR 3; UNCLASSIFIED DRUG; KAG-308; NEW DRUG; PROSTACYCLIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL DIFFERENTIATION; CELL PROLIFERATION; COLON TISSUE; COLONY FORMATION; CONTROLLED STUDY; DRUG RESEARCH; FEMALE; GENE EXPRESSION; GENETIC PROFILE; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; INTESTINE EPITHELIUM CELL; LIMIT OF QUANTITATION; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; THERAPY EFFECT; ULCERATIVE COLITIS; UPREGULATION; ANIMAL; BAGG ALBINO MOUSE; COLON; CYTOLOGY; DISEASE MODEL; DRUG EFFECT; INTESTINE MUCOSA; ORGANOID; PATHOLOGY; STEM CELL;

ANIMALS; COLITIS, ULCERATIVE; COLON; DISEASE MODELS, ANIMAL; DRUGS, INVESTIGATIONAL; EPOPROSTENOL; FEMALE; HUMANS; INTESTINAL MUCOSA; MICE; MICE, INBRED BALB C; MICROARRAY ANALYSIS; ORGANOIDS; STEM CELLS;

EID: 85059273337     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-018-01540-y     Document Type: Article

References (30)

1. Arora Z, Shen B. Biological therapy for ulcerative colitis. Gastroenterol Rep. 2015;3:103–9.
2. Ordas I, Eckmann L, Talamini M, et al. Ulcerative colitis. Lancet. 2012;380:1606–19.
3. Neurath MF. New targets for mucosal healing and therapy in inflammatory bowel diseases. Mucosal Immunol. 2014;7:6–19.
4. Harbord M, Eliakim R, Bettenworth D, et al. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: current management. J Crohns Colitis. 2017;11:769–84.
5. Okamoto R, Watanabe M. Role of epithelial cells in the pathogenesis and treatment of inflammatory bowel disease. J Gastroenterol. 2016;51:11–21.
6. Valatas V, Vakas M, Kolios G. The value of experimental models of colitis in predicting efficacy of biological therapies for inflammatory bowel diseases. Am J Physiol Gastrointest Liver Physiol. 2013;305:G763–85.
7. + stem cell. Nat Med. 2012;18:618–23.
8. Sato T, Vries RG, Snippert HJ, et al. Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche. Nature. 2009;459:262–5.
9. Hibiya S, Tsuchiya K, Hayashi R, et al. Long-term inflammation transforms intestinal epithelial cells of colonic organoids. J Crohns Colitis. 2017;11:621–30.
10. MacFie TS, Poulsom R, Parker A, et al. DUOX2 and DUOXA2 form the predominant enzyme system capable of producing the reactive oxygen species H2O2 in active ulcerative colitis and are modulated by 5-aminosalicylic acid. Inflamm Bowel Dis. 2014;20:514–24.
11. Miyoshi H, VanDussen KL, Malvin NP, et al. Prostaglandin E2 promotes intestinal repair through an adaptive cellular response of the epithelium. EMBO J. 2017;36:5–24.
12. Kawahara K, Hohjoh H, Inazumi T, et al. Prostaglandin E2-induced inflammation: relevance of prostaglandin E receptors. Biochim Biophys Acta. 2015;1851:414–21.
13. O’Callaghan G, Houston A. Prostaglandin E2 and the EP receptors in malignancy: possible therapeutic targets? Br J Pharmacol. 2015;172:5239–50.
14. Watanabe Y, Murata T, Amakawa M, et al. KAG-308, a newly-identified EP4-selective agonist shows efficacy for treating ulcerative colitis and can bring about lower risk of colorectal carcinogenesis by oral administration. Eur J Pharmacol. 2015;754:179–89.
15. Fujii S, Suzuki K, Kawamoto A, et al. PGE2 is a direct and robust mediator of anion/fluid secretion by human intestinal epithelial cells. Sci Rep. 2016;6:36795.
16. Planell N, Lozano JJ, Mora-Buch R, et al. Transcriptional analysis of the intestinal mucosa of patients with ulcerative colitis in remission reveals lasting epithelial cell alterations. Gut. 2013;62:967–76.
17. Wong WM, Poulsom R, Wright NA. Trefoil peptides. Gut. 1999;44:890–5.
18. Zwiers A, Fuss IJ, Leijen S, et al. Increased expression of the tight junction molecule claudin-18 A1 in both experimental colitis and ulcerative colitis. Inflamm Bowel Dis. 2008;14:1652–9.
19. Dotti I, Mora-Buch R, Ferrer-Picon E, et al. Alterations in the epithelial stem cell compartment could contribute to permanent changes in the mucosa of patients with ulcerative colitis. Gut. 2017;66:2069–79.
20. Kazanjian A, Noah T, Brown D, et al. Atonal homolog 1 is required for growth and differentiation effects of notch/gamma-secretase inhibitors on normal and cancerous intestinal epithelial cells. Gastroenterology. 2010;139(918–928):928.e911–6.
21. Zheng X, Tsuchiya K, Okamoto R, et al. Suppression of hath1 gene expression directly regulated by hes1 via notch signaling is associated with goblet cell depletion in ulcerative colitis. Inflamm Bowel Dis. 2011;17:2251–60.
22. Lo YH, Chung E, Li Z, et al. Transcriptional regulation by ATOH1 and its target SPDEF in the intestine. Cell Mol Gastroenterol Hepatol. 2017;3:51–71.
23. Sasaki N, Sachs N, Wiebrands K, et al. Reg4+ deep crypt secretory cells function as epithelial niche for Lgr5+ stem cells in colon. Proc Natl Acad Sci USA. 2016;113:E5399–407.
24. Nanakin A, Fukui H, Fujii S, et al. Expression of the REG IV gene in ulcerative colitis. Lab Investig. 2007;87:304–14.
25. Jiang GL, Nieves A, Im WB, et al. The prevention of colitis by E Prostanoid receptor 4 agonist through enhancement of epithelium survival and regeneration. J Pharmacol Exp Ther. 2007;320:22–8.
26. Ruijtenberg S, van den Heuvel S. Coordinating cell proliferation and differentiation: antagonism between cell cycle regulators and cell type-specific gene expression. Cell Cycle. 2016;15:196–212.
27. Xia K, Xue H, Dong D, et al. Identification of the proliferation/differentiation switch in the cellular network of multicellular organisms. PLoS Comput Biol. 2006;2:e145.
28. Tsuchiya K, Nakamura T, Okamoto R, et al. Reciprocal targeting of Hath1 and beta-catenin by wnt glycogen synthase kinase 3 beta in human colon cancer. Gastroenterology. 2007;132:208–20.
29. Okamoto R, Tsuchiya K, Nemoto Y, et al. Requirement of Notch activation during regeneration of the intestinal epithelia. Am J Physiol Gastrointest Liver Physiol. 2009;296:G23–35.
30. Izumi H, Minegishi M, Sato Y, et al. Bifidobacterium breve alters immune function and ameliorates DSS-induced inflammation in weanling rats. Pediatr Res. 2015;78:407–16.